Preoperative radiochemotherapy for resectable localised oesophageal cancer: A controversial strategy

Critical Reviews in Oncology/Hematology

Volumn 75, Issue 3, 2010, Pages 235-242

  Crehange, G ^a   Bonnetain, F ^a   Peignaux, K ^a   Truc, G ^a   Blanchard, N ^a   Rat, P ^b   Chauffert, B ^a   Ghiringhelli, F ^a   Maingon, P ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Evidence based medicine; Oesophageal cancer; Preoperative chemoradiation; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GASTROINTESTINAL TOXICITY; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE CARE; REVIEW; SURGICAL TECHNIQUE; UNSPECIFIED SIDE EFFECT;

EID: 77955427835     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.11.007     Document Type: Review

References (49)

1. Blot W.J., Devesa S.S., Kneller R.W., Fraumeni J.F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
2. Verdecchia A., Mariotto A., Gatta G., Bustamante-Teixeira M.T., Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003, 39:1603-1609.
3. Sant M., Aareleid T., Berrino F., et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003, 14(Suppl. 5):v61-v118.
4. Coebergh J.W., Albreht T. Should the EU also wage war against cancer? And if so, how? Foreword and afterthoughts to this special issue on cancer control at the European level. Eur J Cancer 2008, 44:1341-1344.
5. Siewert J.R., Stein H.J., Feith M., Bruecher B.L., Bartels H., Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg 2001, 234:360-367.
6. Mariette C., Finzi L., Piessen G., Van Seuningen I., Triboulet J.P. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg 2005, 29:39-45.
7. Rohatgi P.R., Swisher S.G., Correa A.M., et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 2006, 106:552-558.
8. Ishida K., Iizuka T., Ando N., Ide H. Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese institutions trial. Jpn J Clin Oncol 1996, 26:310-315.
9. Akiyama H. Surgery for cancer of the esophagus 1990, Williams and Wilkins, Baltimore.
10. Tam P.C., Siu K.F., Cheung H.C., Ma L., Wong J. Local recurrences after subtotal esophagectomy for squamous cell carcinoma. Ann Surg 1987, 205:189-194.
11. Earlam R., Cunha-Melo J.R. Oesophageal squamous cell carcinoma. I. A critical review of surgery. Br J Surg 1980, 67:381-390.
12. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337:161-167.
13. Hulscher J.B., van Sandick J.W., de Boer A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662-1669.
14. Akiyama H., Tsurumaru M., Kawamura T., Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg 1981, 194:438-446.
15. Lerut T., Nafteux P., Moons J., et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004, 240:962-972.
16. Nishihira T., Hirayama K., Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998, 175:47-51.
17. Siewert J.R., Feith M., Stein H.J. Esophagectomy as therapeutic principle for squamous cell esophageal cancer. Chirurg 2005, 76:1033-1043.
18. Hulscher J.B., Tijssen J.G., Obertop H., van Lanschot J.J. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001, 72:306-313.
19. Sasako M., Sano T., Yamamoto S., et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006, 7:644-651.
20. Wijnhoven B.P., Siersema P.D., Hop W.C., van Dekken H., Tilanus H.W. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 1999, 86:529-535.
21. Marsman W.A., Tytgat G.N., ten Kate F.J., van Lanschot J.J. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol 2005, 92:160-168.
22. Ito H., Clancy T.E., Osteen R.T., et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach?. J Am Coll Surg 2004, 199:880-886.
23. Barbour A.P., Rizk N.P., Gonen M., et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg 2007, 246:1-8.
24. Bonenkamp J.J., Hermans J., Sasako M., et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340:908-914.
25. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999, 79:1522-1530.
26. Hartgrink H.H., van de Velde C.J., Putter H., et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004, 22:2069-2077.
27. Siewert J.R., Bottcher K., Stein H.J., Roder J.D. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998, 228:449-461.
28. Apinop C., Puttisak P., Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994, 41:391-393.
29. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6:659-668.
30. Le Prise E., Etienne P.L., Meunier B., et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994, 73:1779-1784.
31. Lee J.L., Park S.I., Kim S.B., et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004, 15:947-954.
32. Nygaard K., Hagen S., Hansen H.S., et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992, 16:1104-1109.
33. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
34. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305-313.
35. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467.
36. Fiorica F., Di Bona D., Schepis F., et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004, 53:925-930.
37. Urschel J.D., Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003, 185:538-543.
38. Malthaner R.A., Wong R.K., Rumble R.B., Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004, 2:35.
39. Gebski V., Burmeister B., Smithers B.M., Foo K., Zalcberg J., Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226-234.
40. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999, 281:1623-1627.
41. Thirion P., Maillard E., Pignon J. Individual patient data-based meta-analysis assessing the effect of preoperative chemoradiotherapy in resectable oesophageal carcinoma. Int J Rad Oncol Biol Phys 2008, 72(Suppl. 1):S71. Meta-analysis of Chemo in Oesophagus Cancer Collaborative Group.
42. Suntharalingam M. Definitive chemoradiation in the management of locally advanced esophageal cancer. Semin Radiat Oncol 2007, 17:22-28.
43. Bedenne L., Michel P., Bouche O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
44. Bonnetain F., Paoletti X., Collette S., et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res 2008, 17:831-843.
45. Crehange G., Bonnetain F., Chauffert B., Rat P., Bedenne L., Maingon P. Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?. Cancer Radiother 2008, 12:365-373.
46. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
47. Stahl M., Walz M.K., Stuschke M., et al. Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: first results of a randomized phase III trial. J Clin Oncol 2007, 25(18S):4511.
48. Matzinger O., Gerber E., Bernstein Z., et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009, 92:164-175.
49. Crehange G., Maingon P., Peignaux K., et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: federation Francophone de Cancerologie Digestive 9102. J Clin Oncol 2007, 25:4895-4901.